Twist Bioscience Customized Libraries for Biologics Discovery Highlighted at PEGS Boston 2019
April 9, 2019
– Proof-of-Concept Data Presented for GPCR Library and Antibody
Optimization Solution –
— Additional Data Demonstrates Power of Twist Single-Site Variant
Libraries and Combinatorial Variant Libraries —
SAN FRANCISCO & BOSTON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/DNA?src=hash" target="_blank"gt;#DNAlt;/agt;–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic DNA
using its silicon platform, today announced the presentation of four
posters at PEGS (The Essential Protein Engineering Summit) highlighting
proof-of-concept data validating its GPCR library, antibody optimization
solution to improve antibody therapeutics, and the drug discovery
applicability of two types of synthetic variant libraries.
“Taken together, these data illustrate the robust power of
precisely-defined synthetic libraries to explore all relevant variations
for screening antibody therapeutics,” said Emily M. Leproust, Ph.D., CEO
and co-founder of Twist Bioscience. “As we continue to forward
integrate, we are now able to offer our customers exceptionally high
quality synthetic libraries for their internal discovery efforts and now
we have proof-of-concept data for our biologics discovery platform that
demonstrate the value of our GPCR library as well as our antibody
optimization solution approaches.”
All posters were presented on Monday, April 8, 2019.
Poster Number: A103
The data presented demonstrate that Twist Bioscience’s massively
parallel DNA synthesis platform, combined with advanced molecular
biology technologies for library construction, creates more uniform and
precise variant libraries than any other method for comprehensive
generation and evaluation of functional and non-functional diversity for
protein engineering.
Poster Number: A104
The proof-of-concept data demonstrated that our high-throughput antibody
discovery platform identifies functional antibodies against GPCR targets
within a few months, and can readily develop antibodies with affinities
in the nanomolar range. These antibodies exhibited many modes of action
to modulate GPCR activity.
Poster Number: A105
The data demonstrate that combinatorial variant libraries are powerful
tools that accelerate the exploration of the large variant space in
antibody engineering, pathway engineering, and protein engineering. The
poster highlights Twist Bioscience’s ability to construct complex
high-diversity libraries at confined regions (i.e. CDRs), and introduce
technology advancements to enable the construction of synthetic DNA
libraries with diversity scattered along the length of the construct to
home in on the target of interest.
Poster Number: A106
Rapid
Optimization and Humanization of an Anti-PD1 Antibody
The proof-of-concept data showed that our antibody optimization software
successfully generated antibodies with similar or improved binding
affinity when compared to commercial PD-1 antibodies Keytruda and Opdivo.
About Twist Biopharma Antibody Discovery Solutions: Writing the
Future of Biologics
Twist Biopharma, the biologics discovery division of Twist Bioscience,
offers proprietary antibody discovery and optimization solutions through
partnerships with biotechnology and pharmaceutical companies. Twist
Bioscience has developed a disruptive DNA synthesis platform that
“writes” DNA on a silicon chip. By leveraging its unique technology to
manufacture DNA at scale, Twist is able to construct proprietary and
truly unique antibody libraries precisely designed to match the
sequences that occur in the human body. These “library of libraries”
provide an integral resource for antibody therapeutic discovery and
optimization that can be utilized by pharmaceutical and biotechnology
companies. For more information, visit www.twistbiopharma.com.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology
company that has developed a disruptive DNA synthesis platform to
industrialize the engineering of biology. The core of the platform is a
proprietary technology that pioneers a new method of manufacturing
synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging
its unique technology to manufacture a broad range of synthetic
DNA-based products, including synthetic genes, tools for next-generation
sequencing (NGS) preparation, and antibody libraries for drug discovery
and development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist makes
products for use across many industries including healthcare, industrial
chemicals, agriculture and academic research.
Follow us on Twitter
| Facebook
| LinkedIn
| YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements
other than statements of historical facts contained herein are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, the potential value of Twist’s libraries or its GPCR
library or antibody optimization solution. Such forward-looking
statements involve known and unknown risks, uncertainties, and other
important factors that may cause Twist Bioscience’s actual results,
performance, or achievements to be materially different from any future
results, performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among
others, the risks and uncertainties of the ability to attract new
customers and retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive competition
in synthetic biology could make the products Twist Bioscience is
developing obsolete or non-competitive; uncertainties of the retention
of a significant customer; risks of third party claims alleging
infringement of patents and proprietary rights or seeking to invalidate
Twist Bioscience’s patents or proprietary rights; and the risk that
Twist Bioscience’s proprietary rights may be insufficient to protect its
technologies. For a further description of the risks and uncertainties
that could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk factors
set forth in Twist Bioscience’s Annual Report on Form 10-K filed with
the Securities and Exchange Commission on December 20, 2018 and Twist
Bioscience’s Form 10-Q for the quarter ended December 31, 2018 filed
with the Securities and Exchange Commission on February 11, 2019. Any
forward-looking statements contained in this press release speak only as
of the date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a result
of new information, future events or otherwise.
Contacts
Twist Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
[email protected]
Twist Media Contact:
Angela Bitting
925- 202-6211
[email protected]